Islamophobic Remarks :
The CEO of Vyluma and ophthalmologist Dr. Houman Hemmati stated on the internet that “a barrage of 100 Tomahawk cruise missiles” need to be dropped on a media gathering in Beirut.
Bio :
In addition to co-founding and serving as CMO of two venture-backed ophthalmic pharmaceutical firms, Dr. Hemmati is a cornea specialist with training from a fellowship program. Dr. Hemmati previously held the position of Vice President of New Therapies at Capricor Therapeutics, where he oversaw the creation of the business’ exosome platform for gastrointestinal, cutaneous, and ocular inflammatory illnesses. Additionally, he worked with Allergan as Director of Clinical Development, where he assisted in the planning and management of early- to late-stage clinical trials in the therapeutic area of ophthalmology.
In addition to creating treatments for anterior and posterior segment illnesses, including uncommon inherited retinal diseases like Retinitis Pigmentosa and Stargardt Disease, Dr. Hemmati serves as a consultant for a number of ophthalmology biotech and pharmaceutical businesses.
He is a qualified and board-certified ophthalmologist who practices in a busy academic clinical practice in Los Angeles. He also keeps up with publishing publications on the cost of ophthalmic pharmaceuticals and clinical treatment guidelines. Dr. Hemmati graduated from Stanford University with a bachelor’s degree in biological sciences. He completed the Medical Scientist Training Program at Caltech University to earn his PhD in biology after receiving his MD from UCLA. His training included an internal medicine internship at Stanford Hospital, an ophthalmology residency at Johns Hopkins Hospital’s Wilmer Eye Institute, a post-doctoral fellowship in chemical engineering at MIT under Dr. Robert Langer, and a clinical fellowship in ophthalmology at Harvard Medical School’s Massachusetts Eye & Ear Infirmary.